Organic sales growth:
Q2, 2023: -15% (28)

EBITDA margin:
Q2, 2023: 33% (33)

April 1-June 30, 2023

  • Net sales decreased by 8% to SEK 170 m (184).
  • Sales decreased organically by 15% (+28), currency effect 7%.
  • EBITDA amounted to SEK 56 m (61).
  • EBITDA margin amounted to 33% (33).
  • Profit before tax amounted to SEK 44 m (47).
  • Earnings per share before and after dilution amounted to SEK 1.46 (1.56).
  • Cash flow from operating activities amounted to SEK 28 m (40).

Contact

Adele Horn
Corporate Communications & Investor Relations Manager
Direct: + 46 46 460 26 04
Mobile: + 46 72 206 50 88
www.cellavision.com
adele.horn@cellavision.com

About Us

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 16 local market support organizations covering more than 40 countries. In 2022, sales were SEK 639 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-07-20 07:20 CEST.

Attachments

Interim Report Q2 2023

© Modular Finance, source Nordic Press Releases